Healthcare Triangle Inc. (HCTI) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, HCTI scores 15 out of 100 and carries a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars break down as follows:

• Fundamental Cash Engine: 0 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. This pillar contributes nothing to the score, meaning the business is not currently generating returns on capital or free cash flow.
• Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. Its low score indicates limited supportive institutional signal in the source data.
• Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider-conviction signal.
• Macro Regime Fit: 7 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector sensitivity profile. This is the highest-scoring pillar, but it reflects only neutral market sensitivity rather than a positive edge.
• Forensic Balance Sheet: 2 / 20. Per the Roarable RQD rating, Altman Z is 0.2, Piotroski F is 3/9, and Debt/Equity is 0.5. These readings point to elevated balance-sheet and distress risk.

For a prospective investor, the rating translates to a short list of concerns: the business is loss-making at every level of the SEC financials shown, the balance-sheet forensic metrics sit in the distress range, and the signal pillars offer little counterweight. Upside drivers are limited to the price's depressed level and the modest macro-fit score; valuation cannot be anchored to earnings because EPS and P/E are not available in source data. The rating's verdict is that the risk-adjusted profile is poor, and an investor evaluating this name today would be weighing a forensic-risk profile rather than a cash-generating franchise.

Healthcare Triangle Inc. is a NASDAQ-listed issuer in the Technology sector, within the EDP Services industry. Per the profile, the company is categorized under these classifications. The source data does not describe its products, customer base, or revenue model beyond the sector and industry labels.

Per the SEC financials, the company reported operating and net losses in each of the three periods shown. Per the market data, operating margin and net margin are each -60%, gross margin is 96%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. FY 2025 revenue of $13.9M is above FY 2024 but below FY 2023. Debt is not available in source data for any period.

Per the recent news and catalysts section, the dominant story is a 1-for-20 reverse stock split tied to Nasdaq compliance, reported across several outlets. Per the same section, a headline references an AI engagement that could target about $3.31M a year but remains unsigned, and another references an AI brain-health initiative with an initial focus on Malaysia and Indonesia. All items are tagged as market wire with a yellow light. Risk watch items include the Nasdaq compliance review implied by the split headlines and the unsigned status of the AI engagement. Per the butterfly supply-chain graph, the supply chain is recorded as NONE with no butterfly links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with an empty set of butterfly links and no proprietary signals. The source data therefore does not establish upstream or downstream dependencies, sector correlations, or second-order bottlenecks. An investor should not infer such linkages from this dataset.

• What is the company's EPS, P/E, and EV/EBITDA, which are all absent from the source data and would be needed to anchor valuation?
• What is the status and timing of the Nasdaq compliance review and the 1-for-20 reverse split, and how will the split affect the share count?
• Does the company have any debt, and what is its liquidity position, given that debt is unavailable across all periods and cash is reported for only two periods?
• Is the AI engagement described in the news wire signed, and what revenue would it contribute relative to the reported losses?
• What products and customers drive the reported revenue of $13.9M in FY 2025?